FLT3 and acute myeloid leukemia: In contrast, clinical studies with midostaurin plus standard chemotherapy in patients with FLT3-mutated AML [158], or with midostaurin alone in patients with advanced mast cell lymphoma [160] have shown significant clinical advantages, including improved overall response rates, longer event-free survival times and low toxicities.